Logo image of CLRB

CELLECTAR BIOSCIENCES INC (CLRB) Stock Fundamental Analysis

USA - NASDAQ:CLRB - US15117F8804 - Common Stock

2.9 USD
+0.03 (+1.05%)
Last: 11/14/2025, 8:00:00 PM
2.98 USD
+0.08 (+2.76%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

2

Overall CLRB gets a fundamental rating of 2 out of 10. We evaluated CLRB against 533 industry peers in the Biotechnology industry. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability. CLRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLRB has reported negative net income.
In the past year CLRB has reported a negative cash flow from operations.
CLRB had negative earnings in each of the past 5 years.
In the past 5 years CLRB always reported negative operating cash flow.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CLRB has a worse Return On Assets (-212.28%) than 90.58% of its industry peers.
The Return On Equity of CLRB (-389.34%) is worse than 74.58% of its industry peers.
Industry RankSector Rank
ROA -212.28%
ROE -389.34%
ROIC N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CLRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for CLRB has been increased compared to 1 year ago.
The number of shares outstanding for CLRB has been increased compared to 5 years ago.
There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

CLRB has an Altman-Z score of -34.31. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.31, CLRB is doing worse than 90.77% of the companies in the same industry.
CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.31
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

CLRB has a Current Ratio of 2.15. This indicates that CLRB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.15, CLRB is doing worse than 73.63% of the companies in the same industry.
A Quick Ratio of 2.15 indicates that CLRB has no problem at all paying its short term obligations.
With a Quick ratio value of 2.15, CLRB is not doing good in the industry: 71.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 2.15
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

CLRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -594.48%.
EPS 1Y (TTM)-594.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-276.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CLRB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.5%
EPS Next 2Y19.54%
EPS Next 3Y17.75%
EPS Next 5Y15.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

CLRB's earnings are expected to grow with 17.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.54%
EPS Next 3Y17.75%

More info and screens

0

5. Dividend

5.1 Amount

CLRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (11/14/2025, 8:00:00 PM)

After market: 2.98 +0.08 (+2.76%)

2.9

+0.03 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners3.43%
Inst Owner Change56.24%
Ins Owners0.81%
Ins Owner Change14.72%
Market Cap9.25M
Revenue(TTM)N/A
Net Income(TTM)-29.07M
Analysts80
Price Target85.68 (2854.48%)
Short Float %5.19%
Short Ratio1.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.37%
Min EPS beat(2)14.78%
Max EPS beat(2)15.96%
EPS beat(4)3
Avg EPS beat(4)27.2%
Min EPS beat(4)-5.28%
Max EPS beat(4)83.31%
EPS beat(8)4
Avg EPS beat(8)13.94%
EPS beat(12)6
Avg EPS beat(12)13.31%
EPS beat(16)9
Avg EPS beat(16)10.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-30%
EPS NQ rev (1m)8.31%
EPS NQ rev (3m)36.42%
EPS NY rev (1m)7.34%
EPS NY rev (3m)27.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)-21.39
EYN/A
EPS(NY)-8.82
Fwd EYN/A
FCF(TTM)-10.86
FCFYN/A
OCF(TTM)-10.84
OCFYN/A
SpS0
BVpS2.34
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -212.28%
ROE -389.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 2.15
Altman-Z -34.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)212.71%
Cap/Depr(5y)154.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-594.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-276.67%
EPS Next Y21.5%
EPS Next 2Y19.54%
EPS Next 3Y17.75%
EPS Next 5Y15.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.71%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC / CLRB FAQ

Can you provide the ChartMill fundamental rating for CELLECTAR BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to CLRB.


Can you provide the valuation status for CELLECTAR BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTAR BIOSCIENCES INC (CLRB). This can be considered as Overvalued.


Can you provide the profitability details for CELLECTAR BIOSCIENCES INC?

CELLECTAR BIOSCIENCES INC (CLRB) has a profitability rating of 0 / 10.


What is the financial health of CELLECTAR BIOSCIENCES INC (CLRB) stock?

The financial health rating of CELLECTAR BIOSCIENCES INC (CLRB) is 5 / 10.


What is the earnings growth outlook for CELLECTAR BIOSCIENCES INC?

The Earnings per Share (EPS) of CELLECTAR BIOSCIENCES INC (CLRB) is expected to grow by 21.5% in the next year.